Benitez S, Cordero A, Santamaria PG, Redondo Pedraza J, Rocha AS, Collado Sole A, Jimenez M, Sanz Moreno A, Yoldi G, Santos JC, De Benedictis I, Gomez Aleza C, Da Silva Alvarez S, Troule K, Gomez Lopez G, Alcazar N, Palmero I, Collado M, Serrano M, Gonzalez Suarez E. RANK links senescence to stemness in the mammary epithelia, delaying tumor onset but increasing tumor aggressiveness. Dev Cell. 2021;56(12):1727-doi:10.1016/j.devcel.2021.04.022. IF:12,27.
Ciscar M*, Trinidad EM*, Perez-Montoyo, H, Alsaleem M, Jimenez-Santos MJ, Toss M, Sanz-Moreno A, Vethencourt A, Perez-Chacon G, Petit A, Soler-Monsó MT Gomez-Miragaya J, Gomez-Aleza C, Jimenez M, Dobrolecki, LE, Lewis MT, A Bruna, S Mouron, M Quintela Fandino, F Al-Shahrour, A Martinez Aranda, Sierra A, Green AR, Rakha E and González-Suarez E. RANK expression is an independent factor of poor prognosis in estrogen receptor negative breast cancer and a therapeutic target in patients derived orthoxenografts. Biorxiv 2021. doi: 10.1101/2021.12.13.470911
XY Woo, (60 authors), Enzo Medico*, Jeffrey H. Chuang*, PDXNET consortium & EurOPDX consortium. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet 53, 86–99 (2021). https://doi.org/10.1038/s41588-020-00750-6
Sanz Moreno A, Palomeras S, Pedersen K, Morancho B, Pascual T, Galvan P, Benitez S, Gomez Miragaya J, Ciscar M, Jimenez M, Pernas S, Petit A, Soler Monso MT, Vinas G, Alsaleem M, Rakha EA, Green AR, Santamaria PG, Mulder C, Lemeer S, Arribas J, Prat A, Puig T, Gonzalez Suarez E. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. BREAST CANCER RES. 2021;23(1):42-42. doi:10.1186/s13058-021-01390-2. IF:6,47.
Vethencourt,AC,Trinidad,EM,Aleza,CG,Simon,SP,Petit,A,Soler,T,Urruticoechea,A,Martinez,AG,Garcia Tejedor,A,Pla,MJ,Capo,C,Gil,MG,Stradella,A,Fernadez,A,Penabad,SR,Cejuela,M,Vazquez,S,Iserte,A,Falo,C,Gonzalez Suarez,E. Immunomodulatory effect of denosumab in early breast cancer: Preliminary results of a randomized window-opportunity clinical trial D-Biomark. Ann. Oncol.2021.3226-26.doi:10.1016/j.annonc.2021.03.028.
